bit.bio Partners with myriamed to Add Cryopreserved Stem Cell-Derived Cardiomyocytes to Drug Discovery Portfolio

The cryopreserved cells are supplied ready to plate and show spontaneous, synchronous beating within seven days after thawing, according to the companies.

Key Points

  • bit.bio has partnered with myriamed to add cryopreserved human iPSC-derived cardiomyocytes to its drug discovery portfolio.
  • The portfolio includes ventricular and atrial cardiomyocytes, a dilated cardiomyopathy disease model, and real-time reporter cardiac cells for phenotypic screening.
  • The agreement gives bit.bio offerings across three organ systems commonly assessed for drug safety: heart, liver, and central nervous system.

bit.bio, a Cambridge-based cell programming company, has announced a partnership with German biotechnology company myriamed to bring cryopreserved human iPSC-derived cardiomyocytes into bit.bio’s drug discovery portfolio. Through the exclusive partnership, bit.bio will leverage myriamed’s decade-long cardiac specialization and expertise in 3D tissue modelling to offer ventricular cardiomyocytes and atrial cardiomyocytes, a disease model for dilated cardiomyopathy, and real-time reporter cardiac cells that support phenotypic screening. The suite will also be available for use in bit.bio’s CRISPR screening services.

All cells in the suite are derived from the same donor background, providing a genetically matched system for studying dilated cardiomyopathy phenotypes and for comparative, chamber-specific atrial and ventricular studies. The cardiomyocytes are supplied in a cryopreserved, ready-to-plate format and, according to the companies, exhibit spontaneous, synchronous beating within seven days post-thaw. The cryopreserved cells give researchers immediate access to functional cells without lengthy in-house differentiation protocols, bit.bio said.

myriamed’s cryopreserved cardiomyocytes can be used in customers’ own 3D applications, such as engineered heart tissue, supporting chronic dosing and longer-term studies that 2D monolayers cannot capture. Its genetically matched disease models also allow researchers to study cardiomyopathies and inherited arrhythmic conditions.

Cardiotoxicity and drug-induced liver toxicity are among the primary drivers of drug candidate attrition, fuelled by an early reliance on non-predictive in vitro models, bit.bio noted. Current models, such as animals or immortalised cell lines, do not reflect true human cardiac biology, differing in baseline heart rate and ion channel composition or lacking contractile activity entirely. The companies said the partnership supports the pharmaceutical industry’s ongoing transition toward more human-relevant testing methodologies, in line with regulatory frameworks such as the FDA Modernization Act 2.0.

bit.bio CEO Dr Emma Pepperell said: “By bringing myriamed’s cardiomyocytes into bit.bio’s portfolio, we’re providing researchers with the cells they need to model cardiomyopathy, and use across applications ranging from 2D screening to 3D models, or run a safety screen, all in the same physiologically-relevant background.”

Prof. Wolfram-Hubertus Zimmermann, founder of myriamed GmbH, said: “We are excited about the partnership with bit.bio. With our complementary expertise, built on decades of fundamental research, we are well prepared to serve customers from academia and industry. Our priority has always been the quality of human cell and tissue models, which we are now rolling out to the global drug discovery space.”

The expansion follows bit.bio’s recent launch of ioHepatocytes and its existing neural cells, giving the company products across three major organ systems commonly assessed for drug safety and toxicity.

bit.bio product page

Want to keep up on regenerative medicine? Get the weekly newsletter here.

Discussion

Sign in to join the discussion.

Similar stories